SCHEMBL2673221

SCHEMBL2673221

CCOC(=O)C(Cc1ccccc1OC)C(=O)OCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
TSHR P16473 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
PLIN1 O60240 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
PLIN5 Q00G26 1/20 0.47
ABHD5 Q8WTS1 1/20 0.47
MMP8 P22894 1/20 0.47
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
HPGD P15428 1/20 0.46
MTNR1A P48039 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2426744 0.92 ALDH1A1 (0.46) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL30036768 0.92 ALDH1A1 (0.46) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL20212336 0.87 MTNR1A (0.51) ALDH1A1TSHRMEN1KMT2AMAPT
SCHEMBL20223077 0.86 ALDH1A1 (0.41) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL20212191 0.86 CYP4F2 (0.45) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL491027 0.86 LMNA (0.52) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL19502670 0.86 MMP8 (0.54) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL18342037 0.86 CYP1A2 (0.48) ALDH1A1TSHRMEN1KMT2AMAPT
SCHEMBL28582434 0.86 CYP1A2 (0.48) ALDH1A1TSHRMEN1KMT2AMAPT
SCHEMBL747405 0.86 TSHR (0.51) ALDH1A1TSHRMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
EP-1778236-B1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS INC (US) 2010-07-14 EP disclosed
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
US-7576076-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2009-08-18 US disclosed
EP-1778236-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS Corcept Therapeutics, Inc. (US) 2007-05-02 EP disclosed
WO-2006014394-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2006-02-09 WO disclosed
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2006-02-02 US disclosed
US-20040063729-A1 Microbiocides BAYER CROPSCIENCE K. K. (JP) 2004-04-01 US disclosed
EP-1345940-A2 TRIAZOLOPYRIMIDINES Bayer CropScience K.K. (JP) 2003-09-24 EP disclosed
WO-2002051845-A2 TRIAZOLOPYRIMIDINES BAYER CROPSCIENCE K.K. (DE) 2002-07-04 WO disclosed
US-5270313-A Treatment of circulatory disorders HOFFMANN-LA ROCHE INC. (US) 1993-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators NR3C1, NR3C2, TYMS ALDH1A1 3275/4885TDP1 711/4885TSHR 1038/4885
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS NR3C1, NR3C2, TYMS ALDH1A1 3275/4885TDP1 711/4885TSHR 1038/4885
US-20040063729-A1 Microbiocides FPR1, MPO, FPR2 ALDH1A1 663/4885TDP1 283/4885TSHR 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.